Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the ...

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the ...

Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their ...

Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.

U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early ...

Amid ongoing legal battles over coveted GLP-1 therapies, a drug vendor in Washington state is accused of running an ...

The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The National Institute for Health and Care Excellence (NICE), which decides what drugs are available on the NHS, will rule ...

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

Donanemab is the second disease modifying Alzheimer's drug to be rejected by the National Institute of Health and Care ...

Monday’s lawsuits from Eli Lilly are the first to be filed by the pharma since the regulator officially removed tirzepatide ...